Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease

CARDIAC MAGNETIC RESONANCE UTILITIES IN THE EVALUATION OF ISCHEMIC HEART DISEASE: Topographical Correlation Between Ischemic Territory Injury and Coronary Angiography

The purpose of this study is to evaluate CARDIAC MAGNETIC RESONANCE UTILITIES IN THE ISCHEMIC HEART DISEASE as topographical correlation between ischemic territory injury and coronary angiography.

Assessing the accuracy of Cardio-RM identifying ischemic territories and their correspondence to the presence of critical coronary lesions, comparing the presence, extent and regional inducible ischaemia in the Cardiac-MRI with the presence and characteristics of vascular lesions in coronary angiography.

In particular, the study aims to evaluate the correlation between topography and function of the ischemic area revealed by the resonance and coronary artery disease documented coronary angiography.

Inclusion Criteria:

1. patients with suspected ischemic heart disease or recurrent Myocardial ischemic symptoms defined as:

   • presence of:

     • chest pain related to the effort lasting 5-20 minutes, and / or
     • positive stress test for inducible Myocardial ischemia

   • presence of at least one of the following risk factors: smoke family history of cardiovascular disease hypertension dyslipidemia diabetes mellitus NID / ID

2. no contraindications to perform coronary angiography

3. informed written consent to the processing of personal and sensible data, signed and dated by the patient.

Exclusion Criteria:

• Unstable angina;
• Severe aortic stenosis
• Hypertrophic cardiomyopathy
• Pacemaker and \ or defibrillator
• Coronary stent implantation in 90 days before Cardiac MRI
• Intracranial metal clips
• Severe hypertension (systolic blood pressure> 240 mmHg, and diastolic blood pressure above 120 mmHg)
• Ventricular thrombosis and \ or atrial
• Aortic aneurysm and \ or aortic dissection
• Myocarditis, endocarditis, pericarditis
• Critical stenosis of the left notes
• State of severe anxiety or claustrophobia
• Contraindications to the use of atropine (BAV advanced glaucoma, pyloric stenosis, prostatic hypertrophy)